Latest Breaking News On - Us myeloma innovations research collaborative - Page 1 : comparemela.com

FDA approves Abecma for relapsed, refractory multiple myeloma

FDA approves Abecma for relapsed, refractory multiple myeloma
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Al olaa abdallahBristol myers squibbUs myeloma innovations research collaborativeDrug administrationInnovations research collaborative

FDA approves Abecma as earlier line of therapy for triple-class exposed multiple myeloma

FDA approves Abecma as earlier line of therapy for triple-class exposed multiple myeloma
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Al olaa abdallahKristen dowdBryan campbellByrobert stottUs myeloma innovations research collaborativeUniversity of kansasBristol myers squibbHematologic malignanciesCellular therapeuticsInnovations research collaborative

U S FDA Approves Bristol Myers Squibb and 2seventy bio s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy -April 05, 2024 at 09:08 am EDT

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety.

United kingdomGreat britainBryan campbellBristol myers squibbAl olaa abdallahHemophagocytic lymphohistiocytosisEuropean unionUniversity of kansasUs myeloma innovations research collaborativeExchange commissionDrug administrationImportant safety informationCytokine release syndromeNeurologic toxicitiesMacrophage activation syndromeProlonged cytopenia

U S FDA Approves Bristol Myers Squibb (BMY) and 2seventy bio s (TSVT) Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

U S FDA Approves Bristol Myers Squibb (BMY) and 2seventy bio s (TSVT) Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGreat britainBristol myers squibbBryan campbellAl olaa abdallahHemophagocytic lymphohistiocytosisDrug administrationEuropean unionUniversity of kansasUs myeloma innovations research collaborativeImportant safety informationCytokine release syndromeNeurologic toxicitiesMacrophage activation syndromeProlonged cytopeniaSecondary hematological

FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

United kingdomGreat britainBryan campbellBristol myers squibbAl olaa abdallahUs myeloma innovations research collaborativeUniversity of kansasEuropean unionCell therapySafety studyStandard regimensSubjects with relapsedRefractory multiple myelomaClinical associate professorClinical directorHematologic malignancies